Ditchcarbon
  • Customers
  1. Organizations
  2. Athersys, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 6 days ago

Athersys, Inc.

Company website

Athersys, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for critical medical conditions. Founded in 1998, Athersys has made significant strides in the field of regenerative medicine, particularly through its proprietary MultiStem® cell therapy platform. This unique technology harnesses the power of stem cells to address various diseases, including neurological disorders and cardiovascular conditions. With a strong presence in the US and collaborations across Europe and Asia, Athersys is well-positioned in the competitive biotech landscape. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market reach. Athersys continues to advance its mission of transforming patient care through cutting-edge science and a commitment to improving health outcomes.

DitchCarbon Score

How does Athersys, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

29

Industry Benchmark

Athersys, Inc.'s score of 25 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.

45%

Let us know if this data was useful to you

Athersys, Inc.'s reported carbon emissions

In 2023, Athersys, Inc. reported total Scope 1 emissions of approximately 48,936,000 kg CO2e. This data reflects the company's direct greenhouse gas emissions from owned or controlled sources. Athersys has set a long-term commitment to achieve net-zero emissions across all scopes by 2050, with this target initiated in 2019. While specific reduction targets or achievements for interim years have not been disclosed, the company's commitment to net-zero aligns with industry standards for climate action. Athersys has not reported any Scope 2 or Scope 3 emissions data, indicating a focus primarily on direct emissions at this time. The emissions data is not cascaded from any parent organization, and all figures are derived directly from Athersys, Inc. As the company progresses towards its climate commitments, ongoing transparency in emissions reporting will be crucial for stakeholders.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2023
Scope 1
48,936,000
Scope 2
-
Scope 3
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Athersys, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Athersys, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Athersys, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

EDITA

FI
•
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Predictive Technology Group, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

IntelliCell BioSciences, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Mesoblast Limited

AU
•
Pharmaceutical Preparation Manufacturing
Updated 28 days ago

Alliqua BioMedical, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
dev
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy